Here, the Biomarker Working Group of the HD-RSC summarizes the cross-sectional evidence indicating that regional brain volumes, as measured by volumetric magnetic resonance imaging, are reduced in HD and are correlated with disease characteristics.

The HD Regulatory Science Consortium (HD-RSC) brings together diverse stakeholders in the HD community-biopharmaceutical industry, academia, nonprofit, and patient advocacy organizations-to define and address regulatory needs to accelerate HD therapeutic development. Neuropathological studies show that disease progression follows a characteristic pattern of brain atrophy, beginning in the basal ganglia structures. Huntington's disease (HD) is an autosomal-dominant inherited neurodegenerative disorder that is caused by expansion of a CAG-repeat tract in the huntingtin gene and characterized by motor impairment, cognitive decline, and neuropsychiatric disturbances.

8School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia.

7Huntington's Disease Research Centre, UCL Institute of Neurology, London, United Kingdom.

6Wave Life Sciences, Ltd., Cambridge, MA, United States.

5Teva Pharmaceuticals, West Chester, PA, United States.

4CHDI Management/CHDI Foundation, Princeton, NJ, United States.

3Critical Path Institute, Tucson, AZ, United States.

2Takeda Pharmaceuticals, Ltd., Cambridge, MA, United States.

Scahill 7 Nellie Georgiou-Karistianis 8 * The Huntington's Disease Regulatory Science Consortium (HD-RSC) 3

Clearview value metric mri